Latest Breaking News On - External partnering center - Page 1 : comparemela.com

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities.

United statesLos angelesProduct development centerPrnewswire transcenta holding limitedTranscenta immune tolerance breaking technologyClinical development centers in princetonGroup headquartersTranslational research centerHolding limitedClinical oncology volumeImmune tolerance breaking technologyOrphan drug designationManufacturing facilityClinical development centersExternal partnering centerSuzhou industrial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18 2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18 2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaul beresfordCaroline germaLos angelesProduct development centerClinical development centersTranscenta holdingTranscenta immune tolerance breaking technologyGlobal medicine developmentPrnewswire transcenta holding limitedTranslational research centerGroup headquartersAgilent technologiesHolding limitedInvestigational usePerformance evaluation only

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

United statesCaroline germaLos angelesTranscenta holdingTranscenta immune tolerance breaking technologyTranscenta holding limitedClinical development centers in princetonTranslational research centerProduct development centerGlobal medicine developmentGroup headquartersExecutive vice presidentChief medicalManageable safetyImmune tolerance breaking technologyOrphan drug designation

Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

United statesEvenity romosozumabLos angelesTranscenta holdingChina centerGlobal medicine developmentPrnewswire transcenta holding limitedGroup headquartersTranslational research centerProduct development centerClinical development centers in princetonHolding limitedDrug evaluationExecutive vice presidentChief medicalManufacturing facility

Transcenta Holding Limited (6628 HK) to Hold 2023 ASCO Business Update call Conference

/PRNewswire/ The management team of Transcenta Holding Limited (06628.HK) will attend the 2023 ASCO Business Update Call conference on June 7, 2023..

United statesXueming qianVivian wangLos angelesCaroline germaDaniel wengGroup headquartersTranscenta holdingClinical development centers in princetonTranslational research centerGlobal medicine developmentProduct development centerTranscenta holding limitedUpdate callChief executiveInvestor relations